diagnost tool
deal reiter buy rais pt
although came de minimu level return revenu growth
deliv small beat rel street estim importantli view
deliv materi neg updat result view
bounc result short squeez recent trough week
ago expect volatil like ensu investor probabl weight rang
outcom reiter buy rate rais pt
mix beat street rev y/i top flat y/i
street consum rev y/i beat
ovp rev came ahead us deliv loss
oper margin ahead due lower spend
said core companion rev y/i miss pvd ovp
rev rev declin y/i
expect small deal plan use net proce
recent convert pursu target like europ new zealand australia
expect tuck-in similar optom deal franc think like target
includ spain germani benelux uk recal acquir optom
rev think hand deal compani could
guid indic revenue guid y/i achiev
guarante declin comment segment recal
guid contempl core rev rev y/i off-set
non-cor rev y/i core guid
growth consum growth us imag rev growth
ou imag rev includ rev acquir franc busi
element uf appear track element rc instal begun indic
track launch element uf urin fecal analyz target soft launch
expect soft launch broader launch
indic instal begun element rc rotor chemistri ou help
petvet center pvcc announc extend term
relationship larg corpor account petvet center ye
indic place instal signal high degre
confid pvcc corpor account drive mid-teen annual growth
small base given updat commit econom
long-term target anoth analyst day plan updat lt target
call expect lower previous commun lt target
rev y/i om vs today rev
om compar think
revenu target could hit acquisit think need lower om
target make invest scale busi also announc
host anoth analyst day nyc may
price close busi novemb
anim health diagnost compani
seek take modest us market share gain
expand intern time
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
rais pt newli rais price target use premium multipl
revenu estim discount back year discount rate
use million dilut share outstand previous price target
use multipl revenu estim discount back year
discount rate use million dilut share outstand note
rais multipl assum uf launch time success execut
acquisit target expect deal announc time compani
host next analyst day may
catalyst modest lift launch rotor chemistri ou element
multiplex immunodiagnost analyz news ou expans
improv larg custom pet vet center new tuck-in larger
acquisit launch urine-fec uf analyz
convert note septemb success issu
convert senior note due net compani net proce
roughli net proce use repay outstand
indebted credit facil use collater fulli fund
new credit facil believ access capit help compani fund
new product launch expand commerci across europ like fund
hand small acquisit help scale across europ beyond
ou expans recent tuck-in acquisit franc februari
close acquisit optom france-bas compani design develop
manufactur distribut vet imag product primari focu endoscopi
optom gener rev million euro employe
acquir busi modest sum resourc give
busi beachhead franc see variou opportun across
europ similar other much larger see quit
opportun ou bolt tuck-in tune rev thu think
like remain acquisit mention see opportun
acquir revenu one sever possibl deal ou
busi build australia expect modest revenu contribut heska
also target new partner middl east ukrain eastern europ select
asian countri doesnt coverag
zts/abax impact recent indic see chang field
result zts-abax merger suggest earli think abax
longer donor point share year point share donor
split zts/abax team bundl rotor therapeut
also opin acquir abaxi acceler abil test treat
larg anim health player could follow suit impli mar acquir vca antech
boehring ingelheim bi rev acquir merial anoth
global anim health compani like elanco merck bayer hillhous china
market share dynam earlier year estim market share
anim health diagnost unit state abaxi
noth estim terribl differ
trail survey data suggest abaxi
none/greenfield caution data come
survey respons time tini fraction clinic us
survey data also repres averag last three year like exclud
abaxi recent share loss recent share gain link
recent anim health survey found
move forward combin urin fecal analyz togeth onto one
platform part result combin two expect launch uf
mark delay rel time announc may analyst day
compani origin commun urin fecal
think new product set possibl good growth inflect think
might mark growth compani execut intern expans
possibl addit acquisit benefit traction new product coupl
possibl market share gain unit state
element uf look provid automat imag annual urin sediment
exam manual point-of-car fecal flotat exam complet year
buy unchang target price novemb
diagnost tool
expect launch serv industri first dual urine-fec analyz
size combin opportun urin fecal
indic valid abil combin urin fecal onto one
analyz indic product launch near term
excit uf
hope near-term lift launch element rc rotor-bas chemistri
analyz ou market element multiplex immunodiagnost
platform recent launch
hska element rc analyz design primarili ou custom first-tim
user chemistri analyz element rc abil run test
rotor vs abaxi tests/rotor view competit advantag
compar legaci non-multiplex immunodiagnost platform element
lower cost faster higher sensit allow multiplex roll
element total cortisol assay compris revenu
flow legaci immunodiagnost box intend launch test
heartworm lyme anaplasma ehrlichia like
opinion view test opportun
roughli custom long-term subscript model six-year
term agreement tend monthli minimum
annual price escal target activ subscrib
indic corpor vet hospit us vs
nascent chines market point rise interest veterinari invest
china evidenc hillhous capit group one china largest ventur fund
acquisit chines vet hospit
buy unchang target price novemb
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price novemb
diagnost tool
buy unchang target price novemb
diagnost tool
